![]() Healthcare providers should be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients with eosinophilia. These events may be associated with the reduction of oral corticosteroid therapy. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.Įosinophilic Conditions: Patients being treated for asthma may present with serious systemic eosinophilia sometimes presenting with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis (EGPA), conditions which are often treated with systemic corticosteroid therapy. Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.ĬONTRAINDICATION : DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients. Indication and Important Safety InformationĭUPIXENT is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Please see full Prescribing Information for all indications Subcutaneous Injection: 100 mg/0.67 mL solution in a single-dose pre-filled syringe.Subcutaneous Injection: 200 mg/1.14 mL solution in a single-dose pre-filled syringe.Subcutaneous Injection: 200 mg/1.14 mL solution in a single-dose pre-filled pen.Subcutaneous Injection: 300 mg/2 mL solution in a single-dose pre-filled syringe.Subcutaneous Injection: 300 mg/2 mL solution in a single-dose pre-filled pen.For patients 6-11 years of age with asthma and comorbid moderate-to-severe atopic dermatitis, follow the recommended dosage for atopic dermatitis, which includes an initial loading dose. ![]() 30 kg or more a: 200 mg (1x 200 mg pre-filled pen or syringe) given every 2 weeks.For patients 6-11 years of age with moderate-to-severe asthma.Loading dose of 600 mg (2x 300 mg pre-filled pens or syringes) followed by 300 mg (1 pre-filled pen or syringe) given every 2 weeks.For patients 12 years of age and older with OCS-dependent asthma or with comorbid moderate-to-severe atopic dermatitis or adults with co-morbid chronic rhinosinusitis with nasal polyposis.Loading dose of 400 mg (2x 200 mg pre-filled pens or syringes) followed by 200 mg (1 pre-filled pen or syringe) given every 2 weeks.Loading dose of 600 mg (2x 300 mg pre-filled pens or syringes) followed by 300 mg (1 pre-filled pen or syringe) given every 2 weeks or.For patients 12 years of age and older with moderate-to-severe asthma with an eosinophilic phenotype.DUPIXENT can be administered in the office under the guidance of a healthcare provider if the caregiver is not an appropriate candidate for administration. ![]() In children 6 to less than 12 years of age, DUPIXENT should be given by a caregiver. Patients 12 years of age and older may self-inject DUPIXENT–or a caregiver may administer DUPIXENT–after training has been provided by a healthcare provider on proper subcutaneous injection technique using the pre-filled syringe or pen. ![]() DUPIXENT is an injectable medicine that is administered by subcutaneous injection and is intended for use under the guidance of a healthcare provider. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |